Amyris, Inc. expects to grow revenues and unlock value in its Consumer and Technology Access businesses through the commercialization of new biotech molecules and the sale of non-core assets, among other initiatives.
The firm discussed its plans in a fiscal 2023 first-quarter earnings presentation on 9 May, in which it reported revenue of $56.1m, in line with preliminary numbers it provided a month ago and ahead of the $50m it was targeting in March